2012 Relay For Life of Mcdonald County
2012 Relay For Life of Mcdonald County
2012 Relay For Life of Mcdonald County
INSIDE THIS ISSUE: 2012 Relay for Life of McDonald County Lets kick off the 2012 Relay! Many Colors of Cancer Vendors: Come One, Come All Who do you need to contact? Team Spotlight Be Thinking... Where do we Stand? In the News 1 1 2 2 2 3 3 3 4
PAGE 2
Virginias Army of HopeKidney, Kelly Green and Leukemia, Orange Warriors of HopeOvarian Cancer, Teal
Here is a short list of cancers with their awareness ribbon color. Others are available, so do some research and pick one that is personal to you and to your team!
Team
VOLUME 1, ISSUE 1
PAGE 3
Be Thinking.
For the Relay Event issue of this Newsletter, I want to get you involved! Be thinking about things you might like to see in that issue and let us know! One thing I want to include is a section on why you Relay. Send me an email with a short (30 words or less) why you Relay. Do you have a fundraising event that you would like advertised in the newsletter? Contact information: Scott Johnson [email protected]
Remember - All teams and participants must be registered online. Totals of money earned will only be what is recorded online.
Where Do We Stand?
Teams Debbies Dream Team Misfits Tiny Life Savers Virginias Army of Hope Warriors of Hope Whittenburg Warriors for Christ Corporate Sponsors Arvest Bank, Gold Sponsor Money Raised Highest Earning Teams 1. Debbies Dream Team, $20.00 2. Warriors of Hope, $20.00 3. Highest Earning Individuals 1. Scott Johnson, 150.00 2. Debbie Wishon, $20.00 3. Mark Ward, $10.00
IN THE NEWS: Additional Treatment Helps Some Patients with Rare Brain Tumor Live Longer
In a clinical trial, adding chemotherapy to radiation nearly doubled the survival time for some patients with a rare brain tumor called oligodendroglioma. The patients who benefited had an abnormality called the 1p19q co-deletion in the chromosomes of the tumor. About half of oligodendroglioma patients have the co-deletion. The trial began in 1994 and involved 291 people with an aggressive form of oligodendroglioma. Patients with the co-deletion who were treated with chemotherapy and radiation survived for an average of about 14 years, while those who were treated with radiation alone survived for an average of about 7 years. Patients without the co-deletion survived for about 2 years, whether they received chemotherapy and radiation, or radiation alone. The study was led by the Radiation Therapy Oncology Group (RTOG) and has been submitted for presentation at the American Society of Clinical Oncology (ASCO) meeting in June, 2012. The researchers took the unusual step of announcing the findings before the meeting in order to get the results out to doctors and their patients as soon as possible. Because the study has not yet been published in a peerreviewed medical journal, the results cant be considered final. Researcher Bhupinder Mann, MBBS, a clinical investigator with the National Cancer Institute, said the findings have changed the standard of care for patients with the codeletion. Dr. Mann said, This is a relatively rare form of brain cancer. Its a big result that the survival doubled. The findings have already had an impact on 2 ongoing trials that are studying treatments for brain tumors. In the trials, called CATNON and CODEL, all patients with the codeletion are now being treated with chemotherapy and radiation. February 7, 2012 By: Stacy Simon www.cancer.org/cancer/ news